CHOONG ANG VACCINE LABORATORY Q3 profit from the main business KRW 1.6 billion, up 2.9% from a year earlier
AI summary · Not investment advice
Central Vaccine sold KRW 11.5 billion in Q3 and earned KRW 1.6 billion from its main business, up 2.9% from a year earlier and 39.3% from the prior quarter.
Operating profit · 3 months
KRW 1.6 billion
Key facts
- Revenue (3 months)
- KRW 11.5 billion
- Net income (3 months)
- KRW -146.4 million
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 11.0 billion
- Revenue (year to date)
- KRW 36.0 billion
- Operating profit (prior-year 3 months)
- KRW 1.5 billion
- Operating profit (year to date)
- KRW 5.7 billion
- Net income (prior-year 3 months)
- KRW 1.7 billion
- Net income (year to date)
- KRW 4.5 billion
Commentary
AI commentary · Not investment advice
What happened
Jungang Vaccine filed its quarterly report for the 3rd quarter of 2026, on a standalone basis. Sales for the latest 3 months were KRW 11.51 billion. That is up 4.8% from a year earlier and down 3.3% from the previous quarter.
In the company's terms
Operating profit (profit from its main business) for the 3 months was KRW 1.59 billion. That is up 2.9% from a year earlier and up 39.3% from the previous quarter.
What changes for shareholders
Net income (final profit after taxes and other costs) for the 3 months was a loss of KRW 146.4 million. A year earlier, the same period had a profit of KRW 1.70 billion. The company swung to a loss compared with both that period and the previous quarter.
For the year to date (January 1 to September 30), sales were KRW 36.00 billion. Operating profit was KRW 5.73 billion. Net income was KRW 4.48 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
C